XSHE
002511
Market cap1.32bUSD
Oct 09, Last price
7.04CNY
1D
1.73%
1Q
0.86%
Jan 2017
-9.79%
IPO
5.51%
Name
C&S Paper Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
C&S Paper Co.,Ltd, established in 1979 and headquartered in Zhongshan, China, operates as a manufacturer and seller of household paper goods throughout Mainland China. Its primary product line features an extensive selection of items such as paper rolls, facial tissues, coreless rolls, tissue handkerchiefs, wipes, personal care products, baby diapers, and cotton tissues. The company has also diversified its offerings to include medical devices, disposable medical products, disinfectants, and medical face masks. Furthermore, its business scope extends to general merchandise, kitchenware, sanitary ware, daily sundries, non-woven fabrics and their products, polymer materials and their products, wood pulp, and various baby products, in addition to providing warehousing services. C&S, Sun, and Dolemi are the brands under which its products are sold.
Key people
Bo Gao
President, Chief Financial Officer, Director · since 2025
Peng Liu
Chairman of the Board · since 2025
Guanjie Deng
Vice Chairman of the Board · since 2020
Geyu Liang
Director, Vice President, Secretary of the Board · since 2025
Tiande Lin
Vice President · since 2021
Yuzhao Yang
Executive Chairman of the Board · since 2026
Bai Lu
Chief Content Officer · since 2023
Guanbiao Deng
Vice Chairman of the Board · since 2026
Yang Zhang
Vice President · since 2025
Guangrui Ge
Independent Director · since 2023
Guoquan He
Independent Director · since 2021
Independent Director · since 2024
Headquarters & legal address
中山市东升镇坦背胜龙村;增设一处经营场所具体为:中山市西区彩虹大道136号(B1幢三层、四层、五层及梯间)
中山市, GD 100000
CN
中山市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||